Anti-tumor activity in patients by IHC expression analysis and NGS-identified osimertinib resistance mechanisms.
tumor, IHC-negative
TUMOR
Waterfall plot displaying best percent change from baseline in sum of diameters of target lesions among 20 patients who had tumor samples available for exploratory analysis using IHC staining for EGFR and MET expression. IHC-positive patients had combined EGFR and MET H-scores ≥400, and IHC-negative patients had combined EGFR and MET H-scores <400. The table below the waterfall plot indicates the type of resistance mechanism identified using NGS. Patients with both EGFR-based and EGFR/MET-independent resistance are categorized as having EGFR-based resistance (Fig. 